Adents serialisation solution chosen by French pharma company to ensure FMD
、
Adents, a leading provider of versatile and easily deployable serialisation and track and trace solutions, had its Adents Prodigi cloud serialisation solution chosen by French pharmaceutical company Cristers to ensure compliance with the EU Falsified Medicines Directive (FMD) and provide beyond-compliance ROI.
Jointly developed with Microsoft and powered by Azure, Adents Prodigi allows for secure data exchange and helps leverage the power of serialisation data to improve business practices.
Cristers markets generic and OTC products, and is a French Lab owned by a cooperative of pharmacists. Holding a marketing authorisation for more than 400 products, Cristers differentiates itself with clear and handy packaging to facilitate communication with patients.
While searching for a serialisation solution that would ensure compliance with the FMD, Cristers also sought a means of enabling easy exchange of serialisation data with its supply chain partners, including contract manufacturers and logistics providers.
Additionally, Cristers wanted a solution that would aid in the onboarding of more than 30 European partners – including CMOs, vendors and third-party logistics providers – and facilitate connection with a diverse set of Levels 3 & 4 serialisation solutions.
Adents serialisation solutions are designed to help companies gain simplified speed to compliance with regulatory requirements.
The Adents Prodigi cloud-based Level 4 traceability solution met all of Cristers’ needs.
The solution centrally manages regulatory requirements, provides an easy onboarding process to connect multiple trading partners, and facilitates significant business improvements by enabling companies to utilise the massive amounts of data generated during the serialisation and track & trace process.
“Adents Prodigi solution was the best native cloud Level 4 solution that offers us scalable and cost-efficient IT architecture in addition to a quick and easy partners onboarding,” said Hervé Abou, Head Pharmacist of Cristers.
“Our prequalified software saves time during the validation phase, provides ultimate data security, and offers tremendous advanced analytics capabilities – enabling companies to move beyond compliance to improve business practices.” Added Christophe Devins, founder and CEO of Adents.
Looking for chemical products? Let suppliers reach out to you!
2026-06-26
-
Life Sciences Industry Overview
The coverage spans the global life sciences industry across pharmaceuticals and food & nutrition, tracking the shift from lowest-cost sourcing to supply continuity, quality, and risk management, along with product trends and the growing edge of differentiated, globally capable players.Published in: June.2026
Trade Alert
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Related News
-
Novo Nordisk Reports Theft of Six Drug Batches in India Authorities Warn of Severe Patient Safety Risks
-
Glenmark Recalls Over 110000 Bottles of BP and COPD Drugs in US Due to Safety Concerns
-
Parliamentary Panel Urges Expanded Price Controls as Dozens of Cancer Drugs Remain Unregulated
-
NHU and Sinopec Advance Liquid Methionine Project
-
Innogen Targets 2026 Obesity Drug Market With Trials to Wrap in 2025
-
China Signals Openness to WTO Reforms Tariff Talks Ahead of 2026 Meeting
-
China Extends Anti-Dumping Duties Up to 103.1 Percent on Steel Imports
-
US Vietnam Trade Deal Slashes Tariffs to 20 Percent Avoids Economic Clash
-
US Resumes Ethane Exports to China 240000 Barrels Per Day Back on Track
-
AbbVie Invests $2.1 Billion in Capstan Therapeutics Transforming CAR-T Landscape
Recommend Reading
-
32 Pharma Deals in 2025 First Half Signal Industry Shift Amid Policy Uncertainty
-
NHU Projects Profit Surge of Up to 70 Percent in H1 2025 Reaching 37.5 Billion Yuan
-
Eli Lilly to Raise UK Mounjaro Price 170 Percent Monthly Cost Jumps from £122 to £330
-
FDA Approves Precigen’s Papzimeos Immunotherapy 51 Percent of RRP Patients Avoid Surgery for One Year
-
Eli Lilly Strikes $1.3 Billion AI Deal with Superluminal for Next-Gen Obesity Drugs Targets GPCR Breakthrough
-
Methylene Chloride Market Hits Bottom and Stabilizes, with Supply Contraction Driving a Moderate Recovery
-
Lula’s Disapproval Hits 2024 Low at 51 Percent Support Surges Among Poor and Women After US Tariff Dispute
-
Supply Tightening Dominates the Market, Acrylic Acid Prices Steady with an Uptick
-
Australia New Zealand Approve GM Enzyme Stevia Sweetener From China for Food Use
-
Styrene-Butadiene Rubber Market Trends Slightly Down